Clinical Trial

Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases

Study acronym: RXIM002
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-22.
Status change: Not Yet Recruiting → Recruiting 2026-01-21
Trial Details
NCT Number NCT07322718
Lead Sponsor Ruijin Hospital
Collaborators: RiboX Therapeutics Ltd.
Conditions Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Enrollment 27 participants
Start Date 2025-12-24
Primary Completion 2027-12-19 (estimated)
Study Completion 2028-03-19 (estimated)
Updated on ClinicalTrials.gov 2026-01-23